




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |  |   |
|---|--|--|---|
| (51) International Patent Classification 6 :<br><b>C12N 15/86, A61K 48/00, C12N 5/10, 5/06, A61F 2/02, C07K 14/52</b>   |  | A2   | (11) International Publication Number: <b>WO 97/49827</b>   |
|   |  | (43) International Publication Date: 31 December 1997 (31.12.97) |   |
| (21) International Application Number: PCT/US97/11229<br>(22) International Filing Date: 26 June 1997 (26.06.97)<br>(30) Priority Data: 08/672,461 26 June 1996 (26.06.96) US<br>(60) Parent Application or Grant<br>(63) Related by Continuation<br>US 08/672,461 (CIP)<br>Filed on 26 June 1996 (26.06.96)<br>(71) Applicant (for all designated States except US): CORNELL RESEARCH FOUNDATION, INC. [US/US]; Cornell Business and Technology Park, Suite 105, 20 Thornwood Drive, Ithaca, NY 14850 (US).<br>(72) Inventors; and<br>(75) Inventors/Applicants (for US only): CRYSTAL, Ronald, G. [US/US]; 13712 Canal Vista Court, Potomac, MD 20852 (US). MAGOVERN, Christopher, J. [US/US]; Apartment 33F, 435 E. 70th Street, New York, NY 10021 (US). ROSENGART, Todd [US/US]; 2 Dogwood Lane, Tenafly, NJ 07670 (US). HOFFMAN, Lloyd [US/US]; 11 Lincoln Road, Great Neck, NY 11021 (US). TALMOR, Mia |  |  | [US/US]; Apartment 29A, 1320 York Avenue, New York, NY 10021 (US).<br>(74) Agents: KILYK, John, Jr. et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, Chicago, IL 60601-6780 (US).<br>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br>Published<br>Without international search report and to be republished upon receipt of that report. |

(54) Title: ADENOVIRAL MEDIATED GENE TRANSFER IN ADIPOCYTES AND RELATED IMPLANTS



## (57) Abstract

The present invention provides gene transfer to adipocytes mediated by adenovirus and, in particular, transfer of toxic genes as a means of reducing adiposity and transfer of genes encoding angiogenic substances to induce new blood vessel growth, as well as adipose tissue implants.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |  | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

## ADENOVIRAL MEDIATED GENE TRANSFER IN ADIPOCYTES AND RELATED IMPLANTS

5

TECHNICAL FIELD OF THE INVENTION

The present invention relates to modified adipocytes and  
10 vectors useful for the adenoviral-mediated transfer of genes  
to adipocytes. The present invention also relates to  
implants made from adipose tissue modified by treating the  
adipose tissue with angiogenic and/or other therapeutic  
factors.

15

BACKGROUND OF THE INVENTION

Gene therapy entails the use of genetic information as  
the pharmacologic agent. While originally conceived as a  
means of treating hereditary disease, gene therapy is now  
20 recognized as a powerful tool for delivering therapeutic mRNA  
or proteins for local and/or systemic use (see, e.g.,  
Friedmann, Science, 244, 1275-1281 (1989); Miller, Nature,  
357, 455-460 (1992)). Generally, there are two approaches to  
gene therapy: *ex vivo* and *in vivo*. In the *ex vivo* approach,  
25 cells removed from a host are genetically modified *in vitro*  
before being returned to the host (see, e.g., U.S. Patent  
5,399,346 (Anderson et al.)). In the *in vivo* approach, the  
genetic information itself is transferred directly to the  
host, without employing any cells as a vehicle for transfer.

30 Both approaches have been employed to transfer a so-  
called "therapeutic" gene to a host. Broadly considered, a  
therapeutic gene is a gene that corrects or compensates for  
an underlying protein deficit or, alternately, a gene that is  
capable of regulating another gene, or counteracting the  
35 negative effects of its encoded product, in a particular  
disease state, condition, disorder or syndrome. For  
instance, the *ex vivo* approach has been used for the  
modification of T lymphocytes in the treatment of adenosine

deaminase deficiency, modification of hepatocytes in the treatment of familial hypercholesterolemia, and modification of tumor infiltrating lymphocytes in the treatment of neoplastic disease (reviewed in Setoguchi et al., J.

5 Investig. Dermatol., 102, 415-421 (1994)). The *in vivo* approach has been used, among others, for the treatment of cystic fibrosis and neoplastic disease (Setoguchi et al., *supra*). For the majority of these applications, the coding sequence of the therapeutic gene to be expressed has been  
10 placed under the control of a heterologous promoter (in particular, a constitutive or inducible promoter), generating a recombinant therapeutic gene.

The predominant approach to gene therapy has employed a retrovirus as a vehicle for gene transfer. However,  
15 retroviruses have a number of drawbacks which severely limit their application, particularly *in vivo* (Mastrangeli et al., J. Clin. Invest., 91, 225-34 (1993); Burns et al., Proc. Natl. Acad. Sci., 90, 8033-37 (1993)). Consequently, many researchers have turned to the adenovirus as a vector for  
20 gene therapy (Horwitz, In: Virology, 2nd Ed., Fields et al., eds. (NY: Raven Press, 1990), 1679-1721; Berkner, BioTechniques, 6, 606-629 (1988); Ginsberg (ed.), The Adenoviruses (NY: Plenum Press, 1984); Horwitz, *supra*; Rosenfeld et al., Science, 252, 431-434 (1991); Rosenfeld et  
25 al., Cell, 68, 143-155 (1992); Quantin et al., Proc. Natl. Acad. Sci., 89, 2581-2584 (1992); Crystal et al., Nucleic Acids Res., 21, 1607-12 (1993)). Replication-deficient, recombinant adenovirus vectors are highly efficient at transferring genes *in vitro* and *in vivo*, and currently are  
30 used in a wide variety of applications (see, e.g., Rosenfeld et al. (1991), *supra*; Rosenfeld et al. (1992), *supra*; Crystal et al., Nat. Genet., 8, 42-51 (1994); Lemarchand et al., Circ. Res., 72, 1132-1138 (1993); Guzman et al., Circ. Res., 73, 1202-1207 (1993); Bajocchi et al., Nat. Genet., 3, 229-  
35 234 (1993); Mastrangeli et al., *supra*).

Adenoviruses exist as non-enveloped double-stranded DNA viruses (Horwitz, *supra*). The adenovirus provides an efficient means for transferring biological materials to

target cells (Otero et al., Virology, 160, 75-80 (1987); FitzGerald et al., Cell, 32, 607-617 (1983); Seth et al., Mol. Cell Biol., 4, 1528-1533 (1984); Yoshimura, Cell Struct. Funct., 10, 391-404 (1985); Defer et al., J. Virol., 64, 3661-3673 (1990); Rosenfeld et al. (1991), *supra*; Curiel et al., Proc. Natl. Acad. Sci., 88, 8850-8854 (1991); Rosenfeld et al. (1992), *supra*; Quantin et al., *supra*; Curiel et al., Hum. Gene Therapy, 3, 147-154 (1992)). The adenovirus enters cells by a receptor mediated endocytosis pathway. In the initial virus receptor interaction, the adenovirus binds specific receptors present on the cell surface via fibers on its outer surface (Ginsberg, *supra*; Horwitz, *supra*; Seth et al., In: Virus Attachment and Entry into Cells, Colwell et al., eds. (DC: American Society for Microbiology, 1986), 191-195). Following attachment, the receptors with bound adenovirus cluster in coated pits, and the virus is internalized within a clathrin-coated vesicle and, subsequently, into an endosomal vesicle, termed an endosome, or receptosome (FitzGerald et al., *supra*). The adenovirus ultimately is translocated to the nucleus, where it directs the synthesis of nascent nucleic acids (FitzGerald et al., *supra*; Seth et al. (1984), *supra*; Seth et al. (1986), *supra*; Seth et al., J. Virol., 51, 650-655 (1984a); Seth et al., J. Biol. Chem., 259, 14350-14353 (1984b); Seth et al., J. Biol. Chem., 260, 9598-9602 (1985); Seth et al., J. Biol. Chem., 260, 14431-14434 (1985); Blumenthal et al., Biochemistry, 25, 2231-2237 (1986); Seth et al., J. Virol., 61, 883-888 (1987)).

The ability of the adenovirus to easily enter cells has been seized upon as a means of transporting macromolecules into cells (Otero et al., *supra*; FitzGerald et al., *supra*; Seth et al. (1984), *supra*; Yoshimura, *supra*; Defer et al., *supra*; Rosenfeld et al. (1991), *supra*; Curiel et al. (1991), *supra*; Rosenfeld et al. (1992), *supra*; Quantin et al., *supra*; Curiel et al. (1992), *supra*). There are two means by which such transfer has been effected. First, the adenovirus has been employed to transfer non-viral macromolecules packaged

within the adenovirus either in place of, or in addition to, normal adenoviral components (Rosenfeld et al. (1991), *supra*; Rosenfeld et al. (1992), *supra*; Quantin et al., *supra*; Berkner, *supra*). Second, the adenovirus has been employed to mediate the transfer of non-viral macromolecules either linked to the surface of the adenovirus (e.g., by means of conjugation of the nucleic acid through a polylysine residue to an antibody to adenoviral capsid protein (Curiel et al. (1992), *supra*)) or in a "bystander" process where the macromolecule is cointernalized and taken along as cargo in the adenoviral receptor-endosome complex (Otero et al., *supra*; FitzGerald et al., *supra*; Seth et al. (1984), *supra*; Yoshimura, *supra*; Otero et al., *supra*; Defer et al., *supra*). Such a bystander process has been employed to enhance the transfer of a variety of non-viral macromolecules including plasmid DNA linked to ligands (Curiel et al. (1991), *supra*; Curiel et al. (1992), *supra*; Cotten et al., Proc. Natl. Acad. Sci., 89, 6094-098 (1992)); Rosenfeld et al. (1992), *supra*; Quantin et al., *supra*; Cotten et al., J. Virology, 67, 3777-3785 (1993); Wagner et al., Proc. Natl. Acad. Sci., 78, 144-145 (1981)), and plasmid DNA unmodified by nonspecific linkers or by linker-ligand complexes (Yoshimura et al., J. Biolog. Chem., 268, 2300-303 (1993); PCT Application WO 95/21259 (Seth et al.)).

Recently, Setoguchi et al. (Setoguchi et al., *supra*) disclosed adenoviral-mediated gene transfer to adipocytes *in vivo* of a replication-deficient recombinant adenoviral vector carrying the coding sequence of the  $\beta$ -galactosidase reporter gene under the control of the Rous sarcoma virus long terminal repeat as a promoter. Similarly, Clayman et al. (Clayman et al., Cancer Gene Therapy, 2, 105-111 (1995)) disclosed that submucosal injection in mice of a recombinant adenoviral vector carrying a  $\beta$ -galactosidase reporter gene produces scattered staining of adipocytes along the needle track.

Other investigators working with vectors and means of delivery other than adenovirus have transferred genes other

than reporter genes to adipocytes *in vivo*. Specifically, Ross et al. (Ross et al., Genes Devel., 1318-1324 (1993)) disclosed the reduction of adiposity via gene transfer to adipose tissue of an attenuated diphtheria toxin A chain under the control of the adipocyte-specific adipocyte P2 (aP2) promoter. Yamaizumi et al. (Yamaizumi et al., Cell, 15, 245-50 (1978)) disclosed cell killing through the introduction of diphtheria toxin fragment A, and Gregory et al. (Gregory et al., PCT Application WO 95/11984) disclosed means of inducing cell death, such as with use of the conditional suicide gene thymidine kinase. Similarly, Graves et al. (Graves et al., Genes & Development, 5, 428-37 (1991)) and Ross et al. (Ross et al., Proc. Natl. Acad. Sci., 89, 7561-65 (1992); Ross et al., Proc. Natl. Acad. Sci., 87, 9590-94 (1990)) each disclosed an adipocyte-specific enhancer located in the 5'-regulatory region of the aP2 gene.

Other references similarly have disclosed methods for deleting specific cell lineages by cell-specific expression of a toxin gene (Palmiter et al., Cell, 50, 435-43 (1987); Bernstein et al., Mol. Biol. Med., 6, 523-30 (1989); Behringer et al., Genes & Development, 2, 453-61 (1988); Hughes et al., PCT Application WO 92/09616)). The method employed typically calls for microinjecting into fertilized eggs a chimeric gene in which a cell-specific enhancer/promoter is used to drive the expression of a toxic gene product. In a modification of this approach, Hughes et al. (Hughes et al., *supra*) disclosed reduction in the amount of fatty tissues of a host due to introduction of a vector encoding the chicken c-ski protein, which induces myogenic differentiation.

References not involving adenovirus as a means of gene transfer suggest further ways in which adipocytes can be modified *in vivo* to achieve specific therapeutic aims. Specifically, Spiegelman et al. (Spiegelman et al., J. Biol. Chem., 268(10), 6823-26 (1993)) reviewed the regulation of adipocyte gene expression and disclosed "influencing metabolism by controlling adipogenic gene expression" and "[interfering] with adipogenesis and systemic metabolism by

targeting these key regulators" associated with cell differentiation or obesity. Graves et al. (Graves et al., *supra*) disclosed that "the relationship between obesity and diabetes in several obese/diabetic mouse models ... could be probed by directly suppressing adipose cell formation and/or lipid accumulation through the delivery of toxins or various receptors affecting lipid accumulation." Ross et al. (Ross et al. (1990), *supra*) disclosed the production of transgenic mice containing the adipocyte-specific aP2 gene regulatory region linked to the coding sequence of a reporter gene as a means of monitoring tissue-specific expression and suggest "adipose-directed expression of exogenous genes may be an effective method to alter fat storage and thus directly manipulate the fatness of transgenic animals." Ross et al. (Ross et al. (1992), *supra*) further disclosed the production of transgenic mice containing the adipocyte-specific aP2 gene regulatory region linked to the simian virus 40 (SV40) transforming genes as a means of directing expression of linked exogenous genes, such as oncogenes, to adipose tissue.

Other references also have relevance to adipocyte modification. Specifically, U.S. Patent 5,268,295 (Serrero) relates to a mammalian adipocyte-specific polypeptide, termed pl54, which is expressed in high quantities in adipogenic cell lines after differentiation. The '295 patent discloses the murine and human pl54 polypeptide, as well as the DNA and RNA molecules coding therefor, methods for its preparation, and antibodies specific for the polypeptide. Flier et al. (Flier et al., *Science*, 237, 405-8 (1987)) disclose that expression of an adipsin gene and, correspondingly, circulating levels of the serine protease homolog are decreased in obesity. More recently, researchers have demonstrated that the protein product (Ob) of the mouse obese gene causes weight loss and maintenance of the weight loss when injected into animals (e.g., reviewed in Barinaga, *Science*, 269, 475-76 (1995)).

Accordingly, there is a need for an improved means of modifying adipocytes by transferring genes thereto. In addition, there is a need for modified adipocytes and adipose



tissue implants. It is an object of the present invention to provide same. These and other objects and advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention  
5 provided herein.

#### BRIEF SUMMARY OF THE INVENTION

The present invention provides methods and vectors to modify adipocytes *in vivo* and *ex vivo*, including adenoviral  
10 mediated gene transfer and other means. The present invention also provides for the *in vivo* transfer of genes to adipocytes to provide a source of proteins to be used in the local milieu of the adipocyte tissue or to be secreted and used systemically. In particular, the present invention  
15 provides for the transfer of toxic genes to adipocytes *in vivo* as a means of reducing adiposity, and the transfer of genes encoding angiogenic substances to induce neovascularization. Furthermore, the present invention provides for the modification and transfer of adipocytes to  
20 other sites within a host, which provides improved transplantation of the adipocytes, a transplantable source of therapeutic or diagnostic biological molecules, and other advantages.

#### BRIEF DESCRIPTION OF THE DRAWINGS

25 **Figure 1** is a graph of dose of AdCMVCAT (total pfu) delivered to rat retroperitoneal adipose tissue versus chloramphenicol acetyl transferase (CAT) conversion (% conversion).

**Figure 2** is a graph of time (days) following vector  
30 (AdCMVCAT) administration to rat retroperitoneal adipose tissue versus relative CAT activity (% conversion/mg protein). The arrow indicates the time of vector administration.

**Figure 3** is a graph of time (days) versus level of VEGF  
35 (ng/mg protein) following AdCMV.VEGF (●) or AdCMV.Null (○) administration to rat retroperitoneal tissue. The arrow indicates the time of vector administration.

Figure 4 is a graph of time (days) versus gross vessel count following AdCMV.VEGF (o), AdCMV.Null (o), sham (⊗) or AdCMV.VEGF (contralateral) (Δ) administration to rat retroperitoneal tissue. The arrow indicates the time of vector administration.

Figure 5 is a graph of time (days) versus capillary number/mm<sup>2</sup> following AdCMV.VEGF (o) or AdCMV.Null (o) administration (10<sup>9</sup> pfu) to rat retroperitoneal tissue. The arrow indicates the time of vector administration.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method of modifying an adipocyte which comprises contacting the adipocyte with an adenoviral vector comprising a promoter and, operably linked thereto, a nucleic acid sequence encoding a therapeutic protein or therapeutic mRNA, i.e., a protein or mRNA capable of exerting a therapeutic effect. Desirably the contacting is done under conditions, particularly *in vivo*, such that entry of the adenoviral vector into the adipocyte is effected, the nucleic acid sequence is expressed, and the therapeutic protein or mRNA effect is thereby produced.

While any suitable adenoviral vector can be utilized for gene transfer to adipocytes, it is preferable to use the following vectors which also are provided by the present invention. For instance, adipocyte gene transfer can be carried out using an adenoviral vector comprising an adipocyte-specific promoter and, operably linked thereto, a nucleic acid sequence encoding a therapeutic protein or therapeutic mRNA. The gene transfer can be carried out using an adenoviral vector comprising a constitutive promoter (e.g., a CMV promoter) and, operably linked thereto, a nucleic acid sequence encoding a protein selected from the group consisting of (i) a secreted protein which acts systemically, (ii) a protein which acts upon or in the vicinity of an adipocyte, (iii) a toxin (especially diphtheria toxin A), (iv) an angiogenic growth factor (especially a vascular endothelial cell growth factor (VEGF, including VEGF<sub>121</sub>, VEGF<sub>165</sub>, or VEGF<sub>189</sub>)), (v) an adipsin

(especially an adipsin which is a serine protease homolog), and (vi) a protein product of the obese gene, namely an Ob protein or leptin (especially an Ob protein from mouse or human). The present invention also provides host cells, particularly cells of adipose tissue, comprising the vectors of the present invention.

To optimize the ability of the adenovirus to enter the cell, preferably the gene transfer is carried out in the absence of neutralizing antibodies directed against a particular adenovirus being introduced in the host. In the absence of such antibodies, there is no possibility of the antibody impeding the adenovirus from binding to and/or entering the cell. It is well within the ordinary skill of one in the art to test for the presence of neutralizing antibodies. In the event the presence of such neutralizing antibodies are an obstacle to the intracellular delivery of an adenovirus, another adenoviral vector, e.g., another serotype adenoviral vector (Crompton et al., J. Gen. Virol., 75, 133-139 (1994)), or another adenovirus vector lacking the epitope against which the antibody is directed, can be employed.

The present invention also provides an adipose tissue implant comprising adipose tissue (e.g., isolated from a donor for implantation into a host) and an angiogenic substance in context with said adipose tissue. The adipose tissue implant can be produced by modifying adipose tissue of a donor animal (including humans) either *in vivo* or *ex vivo* with an angiogenic factor or composition to provide increased vascularization of the adipose tissue used to form the implant. When the implant (i.e., adipose tissue implant) is transferred (implanted) to a second site in the same animal or into an immunologically compatible host (or second animal), the action of the angiogenic factor or composition causes an increase in vascularization compared to implanted tissue that has not been modified or processed with an angiogenic substance or composition. The increased vascularization results in a better supply of nutrients and oxygen to the implant and better removal of waste products

produced by the implant in the second site or host. This improved exchange of nutrients and waste products results in a lower level of adipocyte loss following implantation of the adipose tissue implant. By immunologically compatible is meant a host whose immune system will not or cannot attack and destroy the cells that form the implant such that the implant is substantially eliminated.

The present invention also provides a method of using angiogenic proteins and angiogenic DNAs, as well as pharmaceutical compositions comprising the same, to produce an adipose tissue implant.

### Definitions

A "therapeutic gene" comprises a promoter and a nucleic acid sequence encoding a therapeutic protein or a therapeutic mRNA. Such a therapeutic gene can be subcloned into a vector according to the present invention, such that, upon introduction into a host cell, there will be a discernible change in the intracellular environment (e.g., an increased level of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), peptide or protein, or an altered rate of production or degradation thereof), as further described herein, to provide a therapeutic benefit. A "gene product" is either an as yet untranslated RNA molecule transcribed from a given nucleic acid sequence (e.g., mRNA or antisense RNA) or the polypeptide chain (i.e., protein or peptide) translated from the mRNA molecule transcribed from the aforesaid nucleic acid sequence. A nucleic acid sequence or gene is "recombinant" if the sequence of bases along the molecule has been altered from the sequence in which the nucleic acid sequence or gene is typically found in nature, or if the sequence of bases is not typically found in nature. According to this invention, a therapeutic gene can be wholly or partially synthetically made, can comprise genomic or complementary DNA (cDNA) sequences, and can be provided in the form of either DNA or RNA.

Therapeutic genes include, but are not limited to "angiogenic genes" such as those comprising promoters operably linked to DNA encoding one of the VEGF proteins,

particularly VEGF<sub>121</sub>, VEGF<sub>165</sub>, or VEGF<sub>189</sub>. In addition to the VEGF proteins, aFGF, bFGF, and epithelial growth factor are also illustrative of other angiogenic proteins suitable for use in this inventive method. Angiogenic genes encode

5 "angiogenic mRNAs" and "angiogenic proteins", by which is meant any protein that is capable of mediating blood vessel formation (angiogenesis).

Similarly, a lymphogenic DNA comprises a promoter operably linked to a nucleic acid sequence encoding a

10 "lymphogenic protein" or "lymphogenic mRNA". VEGF-C is a suitable illustration of a lymphogenic protein.

A "promoter" is a DNA sequence that directs the binding of RNA polymerase and thereby promotes RNA synthesis.

"Enhancers" are cis-acting elements of DNA that stimulate or

15 inhibit transcription of adjacent genes. An enhancer that inhibits transcription also is termed a "silencer."

Enhancers differ from DNA-binding sites for sequence-specific DNA binding proteins found only in the promoter (which also are termed "promoter elements") in that enhancers can

20 function in either orientation, and over distances of up to several kilobasepairs (kb), even from a position downstream of a transcribed region. According to the invention, a nucleic acid sequence encoding a therapeutic protein or therapeutic mRNA is "operably linked" to a promoter (e.g.,

25 when both the nucleic acid sequence and the promoter constitute a therapeutic gene) when the promoter is capable of directing transcription of that nucleic acid sequence.

### Vector

30 A "vector" is a molecule (e.g., a virus such as adenovirus) that serves to transfer coding information to a host cell. Any suitable adenoviral vector can be utilized in the present inventive method. Thus, an adenoviral vector utilized in accordance with the present invention can

35 encompass any adenoviral vector that is appropriate for the introduction of nucleic acids into eukaryotic cells and is capable of functioning as a vector as that term is understood by those of ordinary skill in the art. An adenoviral vector

//

in the context of the present invention contains one or more heterologous and/or recombinant sequences, e.g., a therapeutic gene comprising a promoter and a nucleic acid sequence encoding a therapeutic protein or therapeutic mRNA, possibly one or more enhancers or silencers, and the like. A sequence is "heterologous" if it is present in a different genome from which it is typically found.

The adenovirus can be any serotype of adenovirus (see, e.g., Fields Virology, Fields et al. (eds.), 3rd Ed., NY: Raven Press, 1996, 2111-2171) and, preferably, is a serotype that can transduce and/or infect a human cell. Desirably, the adenovirus comprises a complete adenoviral virus particle (i.e., a virion) consisting of a core of nucleic acid and a protein capsid, or comprises a protein capsid to which DNA comprising a therapeutic gene is appended, or comprises a naked adenoviral genome, or is any other manifestation of adenovirus as described in the art and which can be used to transfer a therapeutic gene. In the context of the present invention, any suitable adenoviral genome can serve as, or be a part of, the adenoviral vector. Preferred adenoviral genomes include those derived from Ad5 and Ad2, which are easily isolated from infected cells, are commercially available (e.g., from Sigma Chemical Co., St. Louis, MO), or are generally available from those skilled in the art who routinely maintain these viral stocks.

For the purpose of this invention, the adenovirus employed for transfer of a therapeutic gene can be wild type (i.e., replication-competent). However, it is not necessary that the genome of the employed adenovirus be intact. In fact, to prevent the virus from usurping host cell functions and ultimately destroying the cell, the adenovirus can be inactivated prior to its use, for instance, by UV irradiation. Alternately, the adenovirus can comprise genetic material with at least one modification therein, which can render the virus replication-deficient. Also, the adenovirus can consist of a therapeutic gene linked to an adenoviral capsid, and thus may not possess an adenoviral genome. Moreover, the virus can be coupled to a DNA-polylysine complex containing a ligand (e.g., transferrin)

for mammalian cells such as has been described in the art (see, e.g., Wagner et al., *supra*).

The modification to the adenoviral genome can include, but is not limited to, addition of a DNA segment, rearrangement of a DNA segment, deletion of a DNA segment, replacement of a DNA segment, methylation of unmethylated DNA, demethylation of methylated DNA, and introduction of a DNA lesion. For the purpose of this invention, a DNA segment can be as small as one nucleotide and as large as 36 kilobase pairs (kb) (i.e., the size of the adenoviral genome) or, alternately, can equal the maximum amount which can be packaged into an adenoviral virion (i.e., about 38 kb).

Such modifications to the adenoviral genome can render the adenovirus replication-deficient. Preferably, however, the modification does not alter the ability of the adenovirus to bind to a suitable cell surface receptor. Preferred modifications to the adenoviral genome include modifications in the E1, E2, E3, and/or E4 regions.

The vector utilized in the context of the present invention can comprise sequences so as to constitute any type of suitable vector. For example, the vector can comprise a mammalian expression vector, a vector in which the subcloned coding sequence of the therapeutic gene is under the control of its own cis-acting regulatory elements, or a vector designed to facilitate gene integration or gene replacement in host cells. Preferably the vector comprises an expression vector appropriate for expression of a therapeutic gene in a mammalian (optimally, human) cell.

The vector according to the invention also can comprise a vector other than an adenoviral vector (e.g., a plasmid, phage, liposomal or other viral vector), or a ligation of adenovirus sequences with other vector sequences. However, while these other vectors can be employed, for instance, in the construction of adenoviral vectors, preferably an adenoviral vector (i.e., as compared to a phage, plasmid or other vector) is employed to transfer genes to adipocytes, particularly *in vivo*.

Vector identification and/or selection can be accomplished using a variety of approaches known to those skilled in the art. For instance, vectors containing particular nucleic acid sequences can be identified by hybridization, the presence or absence of so-called "marker" gene functions encoded by marker genes present on the vectors, and/or the expression of particular sequences. In the first approach, the presence of a particular sequence in a vector can be detected by hybridization (e.g., by DNA-DNA hybridization) using probes comprising sequences that are homologous to the relevant sequence. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain marker gene functions such as resistance to antibiotics, thymidine kinase activity, and the like, caused by particular genes encoding these functions present on the vector. In the third approach, vectors can be identified by assaying for a particular gene product encoded by the vector. Such assays can be based on the physical, immunological, or functional properties of the gene product.

#### Therapeutic Gene

The vector used in the context of the present invention can comprise one or more therapeutic genes. Any suitable therapeutic gene can be employed according to the present invention, so long as the therapeutic gene is capable of being transcribed in a cell in which the vector has been internalized.

The therapeutic gene being transferred can comprise DNA which can be as small as one repeat unit (e.g., a nucleotide) and as large as reasonably can be isolated, synthesized, or transferred to a host cell using the methods of the present invention and considering the packaging constraints of viral vectors. The therapeutic gene comprises non-coding sequences (such as a promoter) as well as a nucleic acid sequence encoding a therapeutic protein or therapeutic mRNA. The "nucleic acid sequence" of the therapeutic gene preferably comprises sense or antisense sequences, including ribozymes, or catalytic RNA species such as described in the art (Hampel

14



et al., Nucleic Acids Research, 18, 299-304 (1990); Cech et al., Annual Rev. Biochem., 55, 599-629 (1986)), as well as engineered sequences, or sequences which are not normally present in vivo.

5       The nucleic acid sequence of the therapeutic gene can be in any orientation in the vector. The therapeutic gene nucleic acid sequence can be placed under the control of (i.e., "operably linked to") 5' and/or 3' regulatory sequences (e.g., promoters) which typically either do or do  
10       not control the coding sequence (e.g., the sense or antisense mRNA sequence) in its native form. In particular, any promoter can be substituted for the native promoter of the nucleic acid sequence to generate a recombinant therapeutic gene. Furthermore, the therapeutic gene can contain lesions  
15       including, but not limited to, a missing base or altered base (e.g., an alkylated base), a cyclobutyl dimer, strand breaks, and cross-linking of nucleic acid strands.

      The therapeutic gene typically will exert its effect at the level of RNA or protein for the purpose of treating a  
20       disease or condition. The therapeutic gene can exert its effect at the level of RNA, for instance, by comprising a nucleic acid sequence that encodes a therapeutic mRNA such as an antisense message or ribozyme or a protein which affects splicing or 3' processing (e.g., polyadenylation).  
25       Alternately, the nucleic acid sequence of the therapeutic gene can encode a therapeutic protein which acts by affecting the level of expression of another gene within the cell (i.e., where gene expression is broadly considered to include all steps from initiation of transcription through production  
30       of a processed protein), including, among other things, by mediating an altered rate of mRNA accumulation, an alteration of mRNA transport, and/or a change in post-transcriptional regulation.

      Also, a protein encoded by the nucleic acid sequence of  
35       a transferred therapeutic gene can be employed in the treatment of an inherited disease, such as, e.g., the cystic fibrosis transmembrane conductance regulator cDNA for the treatment of cystic fibrosis. The protein encoded by the

therapeutic gene nucleic acid sequence can exert its therapeutic effect by resulting in cell killing. For instance, expression of the gene itself can lead to cell killing, as with the expression of the diphtheria toxin A gene, or the expression of the gene can render cells selectively sensitive to the killing action of certain drugs, e.g., expression of the HSV thymidine kinase gene renders cells sensitive to antiviral compounds including acyclovir, gancyclovir, and FIAU (1-(2-deoxy-2-fluoro- $\beta$ -D-arabinofuranosyl)-5-iodouracil). This is of particular value in the reduction of adiposity according to the invention, wherein adipocytes are killed by the transferred gene. Similarly, expression of the gene can result in new blood vessel growth, as where the therapeutic gene nucleic acid sequence encodes an angiogenic substance.

Accordingly, the therapeutic gene nucleic acid sequence preferably encodes a protein selected from the group consisting of a secreted protein which acts systemically and a protein which acts upon or in the vicinity of an adipocyte. More preferably, the therapeutic gene nucleic acid sequence encodes a protein selected from the group consisting of a toxin, especially diphtheria toxin A or a similar gene encoding a toxin (Yamaizumi et al., *supra*; Ross et al. (1993), *supra*; Palmiter et al., *supra*; Bernstein et al., *supra*; Behringer et al., *supra*; Hughes et al., *supra*), p154 polypeptide, especially the p154 polypeptide obtained from a human or mouse gene (Serrero, *supra*), an adipsin, especially an adipsin which is a serine protease homolog (Flier et al., *supra*), an Ob protein such as a leptin, especially an Ob protein obtained from a human or mouse obesity gene (Zhang et al., Nature, 372, 425 (1994); Murakami et al., Biochem. Biophys. Res. Commun., 209, 944 (1995); Considine et al., J. Clin. Invest., 95, 2986 (1995)) or OB polypeptides such as have been described in the art (see, e.g., Great Britain Patent Application 2,292,382), and an angiogenic substance such as a growth factor, especially VEGF, particularly VEGF<sub>121</sub>, VEGF<sub>165</sub> (Mühlhauser et al., J. Cell Biochem., 18A, DZ315 (1994)), or VEGF<sub>189</sub>, other angiogenic growth factors

such as have been described in the art (see, e.g., Cid et al., *supra*) and are further described herein.

### Promoter

5 Any promoter (i.e., whether isolated from nature or produced by recombinant DNA or synthetic techniques) can be used in connection with the present invention to provide for gene transcription. The promoter preferably is capable of directing transcription in a eukaryotic (desirably mammalian) cell. The functioning of the promoter can be altered by the presence of one or more enhancers and/or silencers present on the vector. The DNA sequences appropriate for expression in eukaryotic cells (i.e., "eukaryotic promoters") differ from those appropriate for expression in prokaryotic cells. 10 Generally, eukaryotic promoters and accompanying genetic signals are not recognized in or do not function in prokaryotic systems, and prokaryotic promoters are not recognized in or do not function in eukaryotic cells. 15

A comparison of promoter sequences that function in eukaryotes has revealed conserved sequence elements. 20 Generally, eukaryotic promoters transcribed by RNA polymerase II are typified by a "TATA box" centered around position -25 which appears to be essential for accurately positioning the start of transcription. The TATA box directs RNA polymerase to begin transcribing approximately 30 base pairs (bp) downstream in mammalian systems. The TATA box functions in conjunction with at least two other upstream sequences located about 40 bp and 110 bp upstream of the start of transcription. Typically, a so-called "CCAAT box" serves as 25 one of the two upstream sequences, and the other often is a GC-rich segment (e.g., a "GC box" comprised, for instance, of the sequence GGGCGG, or the sequences GCCACACCC and ATGCAAAT). The CCAAT homology can reside on different strands of the DNA. The upstream promoter element also can 30 be a specialized signal such as one of those which have been described in the art and which appear to characterize a certain subset of genes. 35

To initiate transcription, the TATA box and the upstream sequences are each recognized by regulatory proteins which bind to these sites, and activate transcription by enabling RNA polymerase II to bind the DNA segment and properly  
5 initiate transcription. Whereas base changes outside the TATA box and the upstream sequences have little effect on levels of transcription, base changes in either of these elements substantially lower transcription rates (see, e.g., Myers et al., Science, 229, 242-247 (1985); McKnight et al.,  
10 Science, 217, 316-324 (1982)). The position and orientation of these elements relative to one another, and to the start site, are important for the efficient transcription of some, but not all, coding sequences. For instance, some promoters function well in the absence of any TATA box. Similarly, the  
15 necessity of these and other sequences for promoters recognized by RNA polymerase I or III, or other RNA polymerases, can differ.

Accordingly, promoter regions can vary in length and sequence and can further encompass one or more DNA binding  
20 sites for sequence-specific DNA binding proteins and/or an enhancer or silencer. Enhancers and/or silencers can similarly be present on a vector outside of the promoter *per se*. The present invention preferentially employs within a therapeutic gene a constitutive promoter, in particular the  
25 cytomegalovirus (CMV) promoter, for regulating a coding sequence of interest. Such promoters, as well as mutations thereof, are known and have been described in the art (see, e.g., Boshart et al., Cell, 41, 521-530 (1985)). Other promoters, however, also can be employed, such as the Ad2 or  
30 Ad5 major late promoter and tripartite leader, the Rous sarcoma virus (RSV) long terminal repeat, and other constitutive promoters such as have been described in the literature. For instance, the herpes thymidine kinase promoter (Wagner et al., *supra*), the regulatory sequences of  
35 the metallothioneine gene (Brinster et al., Nature, 296, 39-42 (1982)), promoter elements from yeast or other fungi such as the Gal 4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, and the alkaline phosphatase  
/P

promoter, can be employed. Similarly, promoters isolated from the genome of mammalian cells or from viruses that grow in these cells (e.g., adenovirus, SV40, herpes simplex virus, and the like) can be used.

5 Instead of being a constitutive promoter, the promoter can be a promoter which is up- and/or downregulated in response to appropriate signals. For instance, an inducible promoter, such as the IL-8 promoter which is responsive to TNF or another cytokine, can be employed. Other examples of  
10 suitable inducible promoter systems include, but are not limited to, the metallothionine inducible promoter system, the bacterial *lacZYA* expression system, the tetracycline expression system, and the T7 polymerase system. Further, promoters that are selectively activated at different  
15 developmental stages (e.g., globin genes are differentially transcribed in embryos and adults) can be employed.

In addition, a tissue-specific promoter, i.e., a promoter that is preferentially activated in a given tissue and results in expression of a gene product in the tissue  
20 where activated, particularly an adipocyte specific promoter, can be used. Preferred adipocyte-specific promoters according to the invention include the aP2 gene regulatory region (Ross et al. (1990, 1992 and 1993), *supra*) and the p154 polypeptide gene regulatory region (Serrero, *supra*).

25

#### Adenoviral Mediated Gene Transfer To Adipocytes

In adenoviral mediated gene transfer, one or more adenoviral vectors are transferred to a host cell, which is preferably a eukaryotic host cell, optimally an adipocyte.  
30 The eukaryotic host cell can be present *in vitro* or *in vivo*. According to the present invention, the "contacting" of cells with an adenoviral vector of the present invention can be by any means by which the vectors will be transduced into the cell. Such transduction can be by any suitable method.  
35 Preferably the adenoviral vectors will be transduced by means of infection or transduction, i.e., using the natural capability of the virus to enter cells and mediate uptake of bystander macromolecules (e.g., the capability of adenovirus

to undergo receptor-mediated endocytosis). However, the vectors also can be introduced by any other suitable means, e.g., by transfection, calcium phosphate-mediated transformation, microinjection, electroporation, osmotic shock, and the like.

Genes can be effectively transduced into a wide variety of different types of adipocytes. For example, genes can be transferred to cells differing both in number of adenovirus receptors as well as in the affinity of the cell surface receptors for adenovirus. The types of cells to which gene delivery is contemplated *in vitro* or *in vivo* in the context of the present invention include avian cells, fish cells, and mammalian cells including but not limited to rodent, ape, chimpanzee, feline, canine, ungulate (such as ruminant or swine), and, preferably, human cells.

#### Pharmaceutical Compositions

Gene transfer vectors can be made into compositions appropriate for contacting cells with appropriate (e.g., pharmaceutically acceptable) excipients such as carriers, adjuvants, vehicles, or diluents. The means of making such a composition, and means of administration, have been described in the art (see, for instance, Remington's Pharmaceutical Sciences, 16th Ed., Mack, ed. (1980)). Where appropriate, the vectors can be formulated into preparations in solid, semisolid, liquid or gaseous forms such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, and aerosols, in the usual ways for their respective routes of administration. Means known in the art can be utilized to prevent release and absorption of the composition until it reaches the target organ or to ensure timed-release of the composition. A pharmaceutically acceptable form should be employed which does not ineffectuate the compositions of the present invention. In pharmaceutical dosage forms, the compositions can be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. For example, in applying the methods of the present invention

for delivery of a nucleic acid encoding a VEGF polypeptide to cells in need of angiogenic stimulation (e.g., in the enhancement of collateral circulation where there has been vascular occlusion or stenosis or where there is a need for vascularization or increased circulation), such delivery can be employed in conjunction with other means of stimulating angiogenesis, such as, for example, treatment with other angiogenic growth factors, or use in combination with matrigel (a complex mixture of tumor basement membrane components and growth factors) (Mühlhauser et al., Circ. Res., 77, 1077-86 (1995)).

Accordingly, the pharmaceutical composition of the present invention can be delivered via various routes and to various sites in an animal body to achieve a particular effect (see, e.g., Rosenfeld et al. (1991), *supra*; Rosenfeld et al., Clin. Res., 39(2), 311A (1991a); Jaffe et al., *supra*; Berkner, *supra*). One skilled in the art will recognize that although more than one route can be used for administration, a particular route can provide a more immediate and more effective reaction than another route. Local or systemic delivery can be accomplished by administration comprising application or instillation of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising intramuscular, intravenous, peritoneal, subcutaneous, intradermal administration, as well as topical administration.

The composition of the present invention can be provided in unit dosage form wherein each dosage unit, e.g., a teaspoonful, tablet, solution, or suppository, contains a predetermined amount of the composition, alone or in appropriate combination with other active agents. The term "unit dosage form" as used herein refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of the compositions of the present invention, alone or in combination with other active agents, calculated in an amount sufficient to produce the desired effect, in association with a pharmaceutically acceptable diluent,

carrier, or vehicle, where appropriate. The specifications for the unit dosage forms of the present invention depend on the particular effect to be achieved and the particular pharmacodynamics associated with the pharmaceutical composition in the particular host.

Accordingly, the present invention also provides a method of transferring a therapeutic gene to a host, which comprises administering the vector of the present invention, preferably as part of a composition, using any of the aforementioned routes of administration or alternative routes known to those skilled in the art and appropriate for a particular application. The "effective amount" of the composition is such as to produce the desired effect in a host which can be monitored using several end-points known to those skilled in the art. Effective gene transfer of a vector to a host cell in accordance with the present invention to a host cell can be monitored in terms of a therapeutic effect (e.g., alleviation of some symptom associated with the particular disease being treated) or, further, by evidence of the transferred gene or expression of the gene within the host (e.g., using the polymerase chain reaction in conjunction with sequencing, Northern or Southern hybridizations, or transcription assays to detect the nucleic acid in host cells, or using immunoblot analysis, antibody-mediated detection, mRNA or protein half-life studies, or particularized assays to detect protein or polypeptide encoded by the transferred nucleic acid, or impacted in level or function due to such transfer). One such particularized assay described in the examples herein includes the Western immunoassay for the detection of the protein encoded by a VEGF gene.

These methods described herein are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan. Moreover, the effective amount of the compositions can be further approximated through analogy to compounds known to exert the desired effect (e.g., compounds traditionally employed to stimulate angiogenesis can provide guidance in



terms of the amount of a VEGF nucleic acid to be administered to a host).

Furthermore, the preferred amounts of each active agent included in the compositions according to the invention (e.g., per each cell to be contacted, preferably from about 1 to at least about 1000 adenoviral plaque forming units (PFU), more preferably from about 1 to at least about 100 adenoviral PFU, although any suitable amount can be utilized either above, i.e., greater than about 1000 adenoviral PFU, or below, i.e., less than about 1 adenoviral PFU) provide general guidance of the range of each component to be utilized by the practitioner upon optimizing the methods of the present invention for practice either *in vitro* or *in vivo*. The adenoviral vector(s) can be carried in any suitable volume of diluent or carrier. However, it is usually preferred that the concentration of the adenoviral vectors be in the range of  $2 \times 10^7$  to  $2 \times 10^{14}$  pfu/ml, and more preferably about  $10^{10}$  pfu/ml. Moreover, such ranges by no means preclude use of a higher or lower amount or concentration of a component, as might be warranted in a particular application. For instance, the actual dose and schedule can vary depending on whether the compositions are administered in combination with other pharmaceutical compositions, or depending on interindividual differences in pharmacokinetics, drug disposition, and metabolism. Similarly, amounts can vary in *in vitro* applications depending on the particular cell line utilized (e.g., based on the number of adenoviral receptors present on the cell surface, or the ability of the particular vector employed for gene transfer to replicate in that cell line). Furthermore, the amount of vector to be added per cell will likely vary with the length and stability of the therapeutic gene inserted in the vector, as well as also the nature of the sequence. As such, the amount of vector to be added per cell is particularly a parameter which needs to be determined empirically, and can be altered due to factors not inherent to the methods of the present invention (for instance, the cost associated with synthesis). One skilled in the art can

easily make any necessary adjustments in accordance with the exigencies of the particular situation.

Also, for these embodiments, when one or more different vectors (i.e., each encoding one or more different  
5 therapeutic genes) are employed in the methods described herein, the contacting of cells with the various components of the present invention can occur in any order or can occur simultaneously. Preferably the contacting will occur simultaneously. In a preferred embodiment, the component  
10 vectors of the present invention can be mixed together and preincubated prior to contacting the cell. When multiple vectors are to be administered, the cell is preferably contacted with the first vector less than about 6 weeks after, or less than about 6 weeks before, the cell is  
15 contacted with another vector. Even more preferably the cell is contacted with the first vector less than about 2 weeks after, or less than about 2 weeks before, the cell is contacted with another vector.

Adipocytes infected in vivo in accordance with the  
20 present invention can be transferred to another site within the host as a vehicle for the delivery of the protein encoded by the transferred gene to another anatomic locale. Such a transfer can be effected by any suitable technique, such as those that are known in the art (see, e.g., Zhang et al.,  
25 Microsurgery, 15, 269-73 (1994); Boyce et al. Otolaryngol. Clin. North Am., 27, 39-68 (1994); Moscona et al., Ann. Plast. Surg., 33, 500-6 (1994); Krabatsch et al., J. Card. Surg., 10, 46-51 (1995)). The adipocytes so transferred need not be from the same host, or even the same species of host.  
30 Preferably, however, the adipocytes are transferred within the same host.

#### Adipose Tissue Implants

The present inventive adipose tissue implant is adipose  
35 tissue removed from a donor that is treated to increase the vascularity of the adipose tissue implant when it is implanted into a second site in the body of the donor or into an immunologically compatible host. The implant can be made by contacting adipose tissue comprising adipocytes in vivo

24

with an adenoviral vector comprising a promoter operably linked to a nucleic acid sequence encoding an angiogenic protein or mRNA (i.e., the inventive method described above) as well as by other means.

5        While adenoviral vectors are suitable for delivery of angiogenic proteins and mRNAs to the adipocytes of the implant *in vivo*, they also can be employed *ex vivo*. That is, adipose tissue can be removed from a host and contacted with an adenoviral vector comprising an angiogenic gene to make  
10       the implant, which can then be shaped (if appropriate or necessary) and transplanted into a host from which the adipose tissue was originally removed or a second, immunologically-compatible host.

Any suitable means of transferring one or more  
15       angiogenic genes to adipose tissue *in vitro* or *in vivo* to form an implant also can be employed to form the present inventive adipose tissue implant. Angiogenic DNA can be complexed with polylysine conjugates and contacted to the adipose tissue that is to be incorporated into the implant.  
20       Alternatively, the DNA can be co-precipitated in calcium phosphate and contacted with the adipose tissue. Another alternative is to incorporate the angiogenic gene into a viral vector other than an adenoviral vector, e.g., into a retroviral, adeno-associated viral, or herpes viral vector,  
25       having the ability to transduce adipocytes or other cells in the adipose tissue and to contact that vector with the adipose tissue. Additionally, the angiogenic DNA can be transferred to the adipose tissue by way of liposomes, lipid vesicles, or cationic or zwitterionic lipid transfer agents  
30       (e.g., Lipofectamine™, Gibco BRL, Bethesda, MD). The *in vivo* and *in vitro* utilities and limitations of these gene transfer methods are well known to the skilled artisan.

Rather than, or in addition to, the transfer of an angiogenic gene into the cells of the adipose tissue, the  
35       adipose tissue can be treated in any other suitable manner to increase the vascularity of the adipose tissue when implanted into a host.

Thus, while an angiogenic gene that expresses an angiogenic protein, particularly VEGF<sub>121</sub>, VEGF<sub>165</sub>, or VEGF<sub>189</sub> can be usefully employed to form the inventive implant, angiogenic proteins per se also can be usefully employed.

5 The VEGFs, acidic FGF, basic FGF, and epithelial growth factor are illustrative of angiogenic proteins suitable for use in the context of the present invention. Preferably, the adipose tissue is perfused with a solution containing a quantity of angiogenic protein sufficeint to stimulate  
10 angiogenesis. About  $10^{-18}$  to about  $10^{-6}$  grams of active protein/cell, preferably about  $10^{-15}$  to about  $10^{-12}$  grams of active protein/cell, desirably is administered to the adipose tissue to form the implant.

In addition to contacting the adipose tissue with an  
15 angiogenic gene or protein, the present inventive implant is optionally treated with a lymphogenic gene or protein (e.g., VEGF-C). While not wishing to be bound by any particular theory, it is believed that lymphogenesis usefully prevents the pooling of extravasated blood components and lymph from  
20 the site of implantation which helps prevent cell loss from the implant (i.e., shrinkage).

Advantageously, transplanted adipose tissue that has been contacted with an angiogenic gene or protein has improved vascularization when implanted into a host and/or is  
25 less susceptible to cell loss which is manifested by the appearance of shrinkage after transplantation. Additionally, if the adipocytes of the adipose tissue are modified such that they comprise a second therapeutic protein in addition to an angiogenic protein, the increased vascularization  
30 resulting from the angiogenic protein provides for more efficient delivery of the second therapeutic protein to sites outside the adipose tissue.

#### Other Considerations

35 With respect to the transfer and expression of therapeutic genes according to the present invention, the ordinary skilled artisan is aware that different genetic signals and processing events control levels of nucleic acids

and proteins/peptides in a cell, such as, for instance, transcription, mRNA translation, and post-transcriptional processing. Transcription of DNA into RNA requires a functional promoter, as previously described. The amount of transcription is regulated by the efficiency with which RNA polymerase can recognize, initiate, and terminate transcription at specific signals. These steps, as well as elongation of the nascent mRNA and other steps, are all subject to being affected by various other components also present in the cell, e.g., by other proteins which can be part of the transcription process, by concentrations of ribonucleotides present in the cell, and the like.

Protein expression also is dependent on the level of RNA transcription which is regulated by DNA signals, and the levels of DNA template. Similarly, translation of mRNA requires, at the very least, an AUG initiation codon which is usually located within 10 to 100 nucleotides of the 5' end of the message. Sequences flanking the AUG initiator codon have been shown to influence its recognition by eukaryotic ribosomes, with conformity to a perfect Kozak consensus sequence resulting in optimal translation (see, e.g., Kozak, J. Molec. Biol., 196, 947-950 (1987)). Also, successful expression of a therapeutic gene in a cell can require post-translational modification of a resultant protein/peptide. Thus, production of a recombinant protein or peptide can be affected by the efficiency with which DNA (or RNA) is transcribed into mRNA, the efficiency with which mRNA is translated into protein, and the ability of the cell to carry out post-translational modification. These are all factors of which the ordinary skilled artisan is aware and is capable of manipulating using standard means to achieve the desired end result.

Along these lines, to optimize protein production following recombination, preferably the vector employed for transfer of a therapeutic gene further comprises a polyadenylation site following the coding region of the therapeutic gene. Also, preferably all the proper transcription signals (and translation signals, where appropriate) will be correctly arranged on the recombinant

vector such that the therapeutic gene will be properly expressed in the cells into which it is introduced. If desired, the vector also can incorporate splice sites (i.e., splice acceptor and splice donor sites) to facilitate mRNA production. Moreover, if the therapeutic gene being transferred encodes a protein which is a processed or secreted protein or, for instance, functions in an intracellular organelle such as mitochondria or endoplasmic reticulum, preferably the vector further contains the appropriate sequences for processing, secretion, intracellular localization, and the like.

With respect to promoters, coding sequences, therapeutic genes, marker genes, and the like, located on a vector according to the present invention, such elements are as previously described and can be present as part of a cassette, either independently or coupled. In the context of the present invention, a "cassette" is a particular base sequence that possesses functions which facilitate subcloning and recovery of nucleic acid sequences (e.g., one or more restriction sites) or expression (e.g., polyadenylation or splice sites) of particular nucleic acid sequences.

#### Other Uses

The present invention provides methods and vectors for transferring genes to adipocytes which have particular utility with respect to diseases or conditions that can be treated directly by gene transfer to adipocytes. Because of the widespread effects of adipocytes on host metabolism, the adenoviral mediated gene transfer is preferably employed for the treatment of an energy storage disorder, such as a disorder selected from the group consisting of obesity, diabetes, increased body fat deposition, hyperglycemia, hyperinsulinemia, hypothermia, hypertension, hypercholesterolemia, hyperlipidemia, and the like.

The present inventive methods also have utility with respect to the treatment of other diseases or conditions. Specifically, according to the present invention, adenovirus can be employed to transfer genes to adipocytes, and, following establishment of at least a limited infection in

adipocyte tissue, the infected adipocytes can be transferred to another site in the host, at which site the protein encoded by the transferred gene can exert its effect. Using adipocytes as a vehicle for the transfer of the gene in this fashion is advantageous, since adipocytes typically are non-immunogenic, unlike certain other tissue grafts which might be employed as a vehicle to transfer genes.

In particular, this method of the present invention can be employed to deliver proteins such as angiogenic substances or growth factors to areas of ischemia, such as the heart or muscle, or, more generally, in the treatment of ischemic disease. Angiogenesis is the process by which new blood vessels are formed from extant capillaries. Thus, the angiogenic process and the angiogenic factors which regulate the process are relevant to embryonic development, inflammation, and wound healing, and also contribute to pathologic conditions such as diabetic retinopathy, rheumatoid arthritis, cancer, and chronic inflammatory diseases (see, e.g., U.S. Patent 5,318,957 (Cid et al.); Brooks et al., *Science*, 264, 569-571 (1994)). Accordingly, the present inventive approach can further be employed to deliver angiogenic growth factors to a host, or to particular regions of the host, to stimulate angiogenesis as a means to facilitate wound healing, as well as to treat cancer or inflammation (especially inflammation of blood vessels or systemic vasculitis). In particular, the approach can be employed in a method wherein instead of performing a more invasive procedure, such as a coronary bypass operation, a vector comprising an angiogenic gene is injected, and new blood vessels are induced to grow around the blocked region. Genes encoding the following angiogenic growth factors, and which have been described in the art, can be used according to the present invention along with further angiogenic substances: vascular endothelial cell growth factor (VEGF), particularly VEGF<sub>121</sub>, VEGF<sub>165</sub>, or VEGF<sub>189</sub> acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), transforming growth factor, alpha and beta tumor necrosis factor, platelet-derived growth factor, and angiogenin.

Furthermore, adipocytes *in vivo* can be employed as a site for the transfer of a gene encoding a protein which exerts its effects locally in the region of the adipocyte tissue or systemically, as for genes encoding secreted proteins which, following their production in adipocytes, diffuse into the bloodstream. Thus, the present inventive methods and vectors also can be used in the treatment of diseases or conditions not directly associated with adipocytes and/or metabolic processes affected thereby.

For instance, the method preferably can be employed to transfer genes that encode VEGF (particularly VEGF<sub>121</sub> or VEGF<sub>165</sub>), aFGF and bFGF, as well as other angiogenic growth factors which can act locally to stimulate angiogenesis in the setting of tissue ischemia. Adenoviral vector transfer of genes encoding angiogenic substances can be employed to provide high concentrations of such substances in a regional fashion for a sustained period; thus inducing angiogenesis in the local milieu, yet minimizing the risk of chronic overinduction of angiogenesis in the target tissue, and promiscuous induction of angiogenesis in sensitive nondiseased organs, such as the retina or synovium, or in occult tumors (Folkman et al., J. Biol. Chem., 267, 10931-34 (1992)). Similarly, the method preferably can be employed to locally increase sensitivity to 5-fluorouracil (5-FU), cis-platinum, and other chemotherapeutic agents that can act to stimulate a cytopathic effect for the treatment of cancer cells.

For secreted proteins that act systemically, the present inventive methods can be employed using vectors which encode various therapeutic genes. For instance, the therapeutic gene can comprise, but is not limited to, the gene for  $\alpha$ 1-antitrypsin or adenosine deaminase for the treatment of inherited deficiency, factor VIII for hemophilia, other coagulation factors for bleeding disorders, erythropoietin for chronic renal failure and marrow suppressive disorders, proteins for enhancing the host defense response (e.g., antiviral proteins or immunomodulators), and antitumor agents (e.g., tumor suppressor proteins and interferons). Moreover,



the present inventive methods and vectors can further be employed to deliver pharmacologics such as antihypertensives and anticoagulants, or receptor agonists or antagonists, using transfected or infected adipocytes as the means of producing these agents.

In regard to the use of a VEGF protein to induce therapeutic angiogenesis, several studies have demonstrated that the administration of VEGF protein in the setting of ischemia is capable of inducing the development of networks of new blood vessels *in vivo*. A single bolus or repeat administration of VEGF induced increased vascularity and blood flow, and improved both hemodynamic and clinical function in rabbit hind limb models of ischemia (Ferrara et al., Ann. N.Y. Acad. Sci., 752, 246-256 (1995); Takeshita et al., Circulation, 90, II228-II234 (1994); Takeshita et al., J. Clin. Invest., 93, 662-670 (1994a); Bauters et al., Am. J. Physiol., 267, H1263-H1271 (1994)). A similar model has been used to demonstrate a synergistic effect of VEGF and bFGF on angiogenesis *in vivo* (Asahara et al., Circulation, 92, II-365-II-371 (1995)). In a canine model of myocardial ischemia using an ameroid constrictor on the left circumflex coronary artery (LCx), daily administration of VEGF via an indwelling catheter in the distal LCx for 28 days resulted in an increase in collateral blood flow to ischemic myocardium and an increase in the density of intramyocardial distribution vessels (Banai et al., Circulation, 89, 2183-2189 (1994)). Also, in a porcine model of chronic ischemia using an ameroid constrictor, continuous administration of VEGF to the myocardium over 6 weeks resulted in myocardial angiogenesis as demonstrated by magnetic resonance imaging, showing a reduced ischemic zone, less contrast arrival delay, and improved ejection fraction and myocardial wall thickening (Pearlman et al., Nature Med., 1, 1085-1089 (1995)).

Delivery of the VEGF gene (as well as other genes) using a vector-mediated approach is advantageous since gene transfer provides an equivalent of a "sustained-release capsule," providing high concentrations of the therapeutic protein for a sustained period. In comparison, the VEGF

3/

protein and certain other proteins have a very short biologic half-life (e.g., 6 minutes for VEGF) (Takeshita et al.

(1994a), *supra*). While animal models of hind limb ischemia do show induction of angiogenesis with a single intraarterial bolus of the VEGF protein (Takeshita et al. (1994a), *supra*), intramuscular administration for limb ischemia requires repetitive administration over several days (Takeshita et al. (1994), *supra*), as does intracoronary administration for myocardial ischemia (Banai et al., *supra*; Pearlman et al.,

*supra*). In comparison, the AdCMV.VEGF vector can provide sustained expression of the VEGF protein for at least 5 days. Also, gene transfer can be strategized to provide regional delivery of a high concentration of VEGF to the ischemic limb or ischemic myocardium. In comparison, systemic

administration of an angiogenic factor carries the theoretical risk of inducing inappropriate angiogenesis at sites of vascular derangement or at sites where angiogenesis might have major adverse consequences, such as in the retina, the synovium, and occult tumors (Folkman et al., J. Biol. Chem., 267, 10931-10934 (1992)). Finally, systemic administration of VEGF has been reported to cause hypotension in rats (Yang et al., Circulation, 92, I-713

(Abstract) (1995)). Clinical applications for which adenoviral-mediated delivery of VEGF or other genes

(particularly genes encoding angiogenic substances) might be useful include nonbypassable ischemic heart disease or peripheral vascular disease, reinforcement of ischemic anastomoses, and acceleration of wound healing.

In comparison to the use of adenovirus for gene delivery to adipocytes, other gene transfer systems that presently are in clinical trials (e.g., retrovirus, adeno-associated virus, plasmid-liposome complexes, and the use of naked plasmid DNA) (reviewed in Crystal et al., Science, 270, 404-410 (1995)) theoretically could be employed instead. While naked plasmids delivered to a proximal artery appear to provide sufficient VEGF to induce angiogenesis in the rabbit hind limb ischemia model (Takeshita et al., "Therapeutic Angiogenesis Following Arterial Gene Transfer of Vascular

Endothelial Growth Factor in a Rabbit Model of Hind Limb Ischemia", Proc. Natl. Acad. Sci., (1995)) and are being evaluated in a clinical trial (Isner, "Arterial Gene Transfer for Restenosis", Recombinant DNA Advisory Committee (RAC) Report No. 9508-118 (Office of Recombinant DNA Activities, NIH: Bethesda, MD (1995)), expression from naked plasmids delivered *in vivo* is several orders of magnitude less than that observed using an adenovirus vector system (Crystal et al. (1995), *supra*; Nabel et al., Cardiovasc. Res., 28, 445-455 (1994)). For *in vivo* gene transfer, retrovirus vectors are limited secondary to their sensitivity to inactivation *in vivo* and their requirement for target cell proliferation to transfer the new gene (Crystal et al. (1995), *supra*). Plasmid-liposome complexes are relatively inefficient for *in vivo* cardiovascular-related gene transfer (Crystal et al. (1995), *supra*; Nabel et al., *supra*). In contrast, adenoviral vectors have the aforementioned properties that make them ideal for the delivery of genes to adipose tissue as described herein and, particularly, for the delivery of VEGF-related genes for therapeutic angiogenesis. For instance, adenoviral vectors are effective at transferring genes to cardiovascular tissues, with high levels of expression of the gene for at least one week. This is particularly advantageous in view of the short half-life of VEGF protein. Moreover, the self-limited nature of adenoviral-mediated gene expression means a decreased (and decreasing over time) risk of evoking too much angiogenesis in the target tissue. The new gene transferred by an adenoviral vector functions in an epichromosomal position, in contrast to adeno-associated virus and retrovirus vectors that integrate the exogenous gene into the chromosome of the target cell, and thus carry the risk of inappropriately delivering the angiogenic stimulus long after it is needed, and the risk of interference with the regulation/expression of a endogenous gene. Furthermore, adenovirus vectors achieve gene transfer to both dividing and non-dividing cells with high levels of efficiency, and produce localized and sustained levels of protein expression in a number of cardiovascular related

sites, such as skeletal muscle, myocardium, and vascular endothelium, as well as adipose tissue.

In addition to the foregoing uses, the present inventive adipose tissue implants have particular utility in plastic or reconstructive surgery. For example, such implants can be used in breast or penile augmentation.

Additional uses and benefits of the present invention will be apparent to one of ordinary skill in the art.

#### 10 Examples

The following examples further illustrate the present invention and, of course, should not be construed as in any way limiting its scope.

15

#### EXAMPLE 1

20

This example describes the construction of the adenoviral vectors employed in the experiments described further herein and described in Magovern et al., "Regional Angiogenesis induced in Non-Ischemic Tissue by an Adenovirus Vector expressing Vascular Endothelial Growth Factor" (Human Gene Therapy, 8, 215-227 (1997)).

25

Several replication-deficient, recombinant adenoviral vectors were employed to assess gene transfer to adipocytes *in vivo*. These vectors include Ad.RSV $\beta$ gal, AdCMVCAT, and AdCMV.VEGF. Ad.RSV $\beta$ gal is an E1-E3- Ad5-based vector which contains the *Escherichia coli*  $\beta$ -galactosidase coding sequence under the control of the long terminal repeat of the Rous sarcoma virus as a promoter, and which follows the SV40 nuclear localization signal, as previously described

30

(Setoguchi et al., *supra*). AdCMV.VEGF (i.e., AdCMV.VEGF<sub>165</sub>)

35

is a E1a-, partial E1b-, partial E3- adenoviral vector that contains an expression cassette in the E1 position containing the cytomegalovirus (CMV) immediate early promoter/enhancer driving the cDNA for the 165 amino acid form of human VEGF (i.e., VEGF<sub>165</sub>, Muhlhauser et al., Circ. Res., 77, 1077-1086 (1995)). AdCMVCAT is similar to AdCMV.VEGF, but contains the coding sequence for chloramphenicol acetyltransferase (CAT) instead of the sequence for VEGF (Kass-Eisler et al., Proc.

Natl. Acad. Sci., 90, 11498-502 (1993)). AdCMV.Null (which is similar to AdCMV.VEGF, but contains no gene in the expression cassette) was used as a control vector (Williams et al., J. Vasc. Surg., 19, 916-923 (1994)).

5        With respect to construction of AdCMV.VEGF, the cDNA for VEGF<sub>165</sub> including the signal sequence for secretion (Conn et al., Proc. Natl. Acad. Sci., 87, 2628-32 (1990)) was inserted into an expression plasmid (Mühlhauser et al. (1995), *supra*) such that the cDNA was placed under the control of the  
10       constitutive CMV immediate early promoter/enhancer. The expression plasmid also contains the Ad5 sequence from nucleotide 3384 to nucleotide 5778 (i.e., 9.24 to 16.05 map units), which serves as the homologous recombination sequence. The plasmid carrying the cDNA for VEGF<sub>165</sub> was  
15       cotransfected with the plasmid pJM17 (from F. Graham) into 293 cells (ATCC CRL1573; a human embryonic kidney cell line which has been transformed by Ad5 and expresses the E1 region in *trans*). The plasmid pJM17 contains the full length Ad5 DNA (36 kb) and pBRX, a 4.3 kb insert placed in the E1  
20       region, thus exceeding by approximately 2 kb the maximum packaging limit of DNA into the adenoviral capsid (McGrory et al., Virology, 163, 614-17 (1988)). Homologous recombination between the expression plasmid and pJM17 in 293 cells resulted in replacement of the E1 region and pBRX insert with  
25       the expression cassette from the expression plasmid. Ad.RSVβgal and AdCMVCAT were similarly prepared.

      The growth of these E1-deleted adenoviruses is limited to 293 cells. For these experiments, 293 cells transduced with the various vectors were propagated in Improved Minimal  
30       Essential Medium (IMEM) with 10% heat inactivated fetal bovine serum (FBS), 2 mM glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin (all from Biofluids, Rockville, MD). Following cotransfection, individual viral plaques were isolated and amplified in 293 cells, and were purified by  
35       CsCl density purification as previously described (Rosenfeld et al., *supra*). Subsequently, the preparations were dialyzed and stored in dialysis buffer (10 mM Tris-HCl, 1 mM MgCl<sub>2</sub>, pH 7.4) with 10% glycerol at -70 °C. The titer of each viral

stock was determined by plaque assay in 293 cells as previously described; titers consistently ranged between  $5 \times 10^9$  and  $2 \times 10^{11}$  pfu/ml.

5

EXAMPLE 2

This example describes adenoviral-mediated gene transfer to adipocyte tissue *in vivo*.

Male Sprague-Dawley rats (250 to 300 gm) were used for all studies; all procedures and care of animals were in accordance with institutional guidelines. Animals were anesthetized with intramuscular ketamine (100 mg/kg) and xylazine (2 mg/kg), and a midline laparotomy was performed under sterile conditions. The intestines were displaced to the contralateral side of the abdomen, and the retroperitoneal fat was identified. The side of vector administration (right vs. left) was determined pre-operatively in a randomized fashion. A single 6-0 non-absorbable monofilament suture was placed in the center of the adipose tissue to mark the site of injection. The adenoviral vector was administered in a volume of 50  $\mu$ l using a 0.5 ml syringe with a 30 gauge needle. The needle tip was positioned at a depth of 5 mm from the surface of the fat to achieve uniform delivery, evident by the appearance of a small weal. Sham-treated animals had identifying sutures placed, but no vector administration. The intestines were returned to their normal position, and the abdomen was closed in a single layer with non-absorbable suture.

Rats were infected with  $2.2 \times 10^9$  pfu of Ad.RSV $\beta$ gal, and 48 hours later the animals were sacrificed. Sections of rat retroperitoneal adipose tissue were removed and fixed in 4% formalin for 3 hours at 4°C. Gene transfer, in particular, the presence of the lacZ gene product encoded by the  $\beta$ -galactosidase reporter gene, was determined by staining cells with the X-gal reagent (5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside, Boehringer Mannheim Corp., Indianapolis, IN), as previously described (Setoguchi et al., *supra*; Mastrangeli et al., *supra*). Expression of the lacZ gene product was considered positive when the cells stained blue,

particularly in the region of the nucleus. Following infection with Ad.RSV $\beta$ gal, adipocytes stained blue and were visualized (100x) and photomicrographed as darkened regions of the tissue sample. In comparison, non-infected cells did not demonstrate blue staining, and  $\beta$ -galactosidase was not evident in AdCMV.Null treated and naive (untreated) animals. These results confirm that the transfer of the  $\beta$ -galactosidase reporter gene, and the subsequent expression of this gene, occurred in adipocytes *in vivo*.

In similar experiments, AdCMVCAT also was delivered to rat retroperitoneal adipose tissue *in vivo*. Specifically, AdCMVCAT in a total volume of 100  $\mu$ l in doses of 0,  $10^4$ ,  $10^5$ ,  $10^6$ ,  $10^7$ ,  $10^8$ , and  $10^9$  pfu was injected into rat adipose tissue (n = 3 animals/dose). The tissue was harvested after 48 hours, and chloramphenicol acetyltransferase (CAT) levels were quantified by thin layer chromatography and phosphorimager analysis (Kass-Eisler et al., *supra*). The relative CAT activity was reported as percent conversion of chloramphenicol to its acetylated counterpart by chloramphenicol acetyl transferase.

These results (as depicted in Figure 1) demonstrate a higher conversion rate with injection of a higher dose of AdCMVCAT. This presumably is due to increased gene transfer with higher multiplicities of infection. Moreover, the results confirm the transfer of the chloramphenicol acetyl transferase reporter gene to adipocytes *in vivo*. The fact that the graph peaks at a dose of  $10^7$  is a function of the assay becoming saturated at this dose. It is likely that even higher levels of CAT production would be detected at the higher doses but for this saturation.

Furthermore, a time course experiment demonstrated that chloramphenicol acetyl transferase activity can be detected at high levels for up to 7 days following gene transfer, and at lower levels for up to 10 days following gene transfer (Figure 2). For this experiment, about  $10^9$  pfu/50  $\mu$ l AdCMVCAT was delivered to rat retroperitoneal fat. The animals were sacrificed at the indicated times, and CAT

assays were performed. The values were determined as percent CAT conversion, which either was or was not normalized to mg protein. Three animals were sacrificed per condition at each time point.

5 The VEGF gene encoded by the AdCMV.VEGF vector also was delivered *in vivo* to rats. Specifically, rat adipose tissue was injected with either  $10^{11}$  pfu of AdCMV.VEGF or with 50 ng of recombinant human VEGF as a positive control. Rat adipose tissue also was injected with  $10^{11}$  pfu of Ad.RSV $\beta$ gal as a  
10 negative control. Within 24 hours following gene transfer, rat adipose tissue was excised, minced, and bathed in Dulbecco's modified Eagle medium (2 ml/g tissue) for 6 hours at 37°C. Aliquots (25  $\mu$ l) of the medium in which the cells were grown were separated on a 15% polyacrylamide gel under  
15 reducing conditions, transferred to a nitrocellulose membrane, and assayed by standard Western immunoassay procedures using polyclonal antibodies to the first 20 amino acids of the mature human VEGF N-terminus (Tischer et al., J. Biol. Chem., 266, 11947-54 (1991)) with the peptide being  
20 conjugated to a carrier protein, keyhole limpet hemocyanin, using 0.2% glutaraldehyde at a 1:500 dilution and secondary antibody biotinylated for use with a streptavidinalkaline phosphatase conjugate (goat anti-rabbit IgG Bio-Rad  
Laboratories, Inc., Hercules, CA) at a 1:10000 dilution. The  
25 results of the Western assay confirm the transfer of the VEGF gene encoded by the AdCMV.VEGF vector to rat adipocytes *in vivo*, and the production of VEGF<sub>165</sub> protein by the host adipocytes -- i.e., a proper size VEGF protein band was observed with use of the positive control recombinant VEGF,  
30 and upon introduction of AdCMV.VEGF, but not upon introduction of Ad.RSV $\beta$ gal.

The amount of VEGF protein produced was quantified using an enzyme-linked immunoassay (ELISA) for the detection of human VEGF protein (Cytokit Red VEGF enzyme immunoassay,  
35 CytImmune Sciences, College Park, MD). Rat retroperitoneal fat was injected with either the control negative vector AdNull ( $10^{11}$  particles/50  $\mu$ l) or AdCMV.VEGF ( $10^{11}$



particles/50  $\mu$ l) The animals were sacrificed immediately, or 1, 2, 5, 10 or 20 days following vector administration. The fat was excised, minced, and bathed in Dulbecco's Modified Eagle Medium (2 ml/gm tissue) for 6 hours at 37°C to allow  
5 release of secreted proteins from the tissue into the medium. Aliquots (25  $\mu$ l) of the tissue culture medium were loaded into 96-well plates in preparation for the ELISA. The assay was performed according to the manufacturer's instructions, and VEGF concentration was normalized to mg protein. Two  
10 animals were sacrificed per condition at each time point. CAT assays were carried out in triplicate.

As can be seen in **Figure 3**, quantification of VEGF expression in adipose tissue over time confirmed that the administration of AdCMV.Null did not result in significantly  
15 increased levels of VEGF over baseline at any of the time points examined. In comparison, the administration of AdCMV.VEGF resulted in a more than 6-fold increase over baseline VEGF expression, with peak expression occurring about 5 days following vector administration. By day 10,  
20 VEGF levels had returned to baseline. The levels of VEGF in these tissues at 1, 2, and 5 days following AdCMV.VEGF administration were significantly greater than the VEGF levels in tissue following administration of AdCMV.Null ( $p < 0.05$ , each time point). The levels of VEGF on day 0,  
25 obtained immediately following vector administration, were similar to the levels in naive animals, which confirms that the viral preparation was not contaminated with VEGF protein ( $p > 0.8$ ). No increase over baseline levels of VEGF was detected in the serum of treated animals, consistent with the  
30 observation that adenoviral vector delivery provides a localized gene transfer strategy.

Immunohistochemical staining of adipose tissue was carried out to confirm the presence of VEGF protein 48 hours following administration of AdCMV.VEGF. For these  
35 experiments, paraffin sections on slides were blocked with 1.5% goat serum for 20 minutes to prevent nonspecific binding, and then were exposed to primary antibody (rabbit anti-human VEGF; Santa Cruz Biotechnology) at a concentration

of 1 µg/ml for 1 hour. A negative control antibody, rabbit polyclonal antichloramphenicol acetyl transferase (5'→3', Boulder, CO), was applied to a replicate section of each tissue at the same concentration. The test and control  
5 antibodies were diluted with phosphate buffered saline (PBS). The primary antibody was eliminated from a parallel slide as an assay control. The slides were exposed sequentially (30 minutes each) with biotinylated goat anti-rabbit IgG (affinity purified against rat serum proteins), ABC reagents  
10 (Vector Laboratories, Burlingame, CO), and diaminobenzidime (4 minutes) as a substrate for the peroxidase reaction, and were then counterstained with hematoxylin.

The immunohistochemical staining of adipose tissue confirmed the presence of VEGF in the cytoplasm of adipocytes  
15 and endothelial cells in AdCMV.VEGF treated tissue, and its absence in AdCMV.Null treated tissue.

Tissue sections were examined 10 days following gene transfer *in vivo* to determine whether the encoded VEGF gene product exerted any effect on vascularity. Two strategies  
20 were used to determine whether the administration of AdCMV.VEGF to retroperitoneal adipose tissue evoked angiogenesis in the adipose tissue: (1) quantification of blood vessels assessed at the macroscopic level (30x magnification) *in vivo* in living tissue, and (2)  
25 quantification of blood vessels < 20 µm by histology. All studies were carried out using vector doses of 10<sup>9</sup> pfu. Control groups included: injected retroperitoneal adipose tissue immediately after injection; retroperitoneal adipose tissue on the contralateral, untreated side; sham-injected  
30 adipose tissue; and retroperitoneal adipose tissue injected with the AdCMV.Null control vector.

The quantification of the number of macroscopic blood vessels in living tissue was accomplished by injecting retroperitoneal adipose tissue with AdCMV.VEGF (minimum of 3  
35 animals per time point) or AdCMV.Null (minimum of 3 animals per time point) as described above. Immediately thereafter, and 5, 10, 20, and 30 days following vector administration, the animals were anesthetized, the retroperitoneal adipose

40

tissue was exposed, and injected (ipsilateral) and uninjected (contralateral) tissues were examined *in situ* under a dissecting microscope (Nikon SMZ-U, Morrell Instrument Co., Inc., Melville, NY) at a distance of 15 cm (x30).

5 Photographic slides were prepared (Ektachrome 64T; Kodak, Rochester, NY), and the slides projected onto a screen at 3 m. Using the identifying suture as the center, a circle was drawn on the screen around the suture with a diameter that corresponded to a distance of 1 cm *in situ*. The number of  
10 vessels that crossed the circle were counted by 3 blinded observers, with a minimum of three vessels counted per slide per observer. The mean of these 3 counts was reported as the number of macroscopic blood vessels in the 1 cm diameter circle of adipose tissue for each animal at each time point.

15 To quantify the number of vessels  $< 20 \mu\text{m}$  in the adipose tissue,  $1 \text{ cm}^3$  samples of both the ipsilateral (treated) retroperitoneal adipose tissue centered around the identifying suture and the contralateral (untreated) adipose tissue were harvested from the same groups of animals used  
20 for gross vessel quantification. Tissue was rinsed in PBS and stored in 4% formalin at  $4^\circ\text{C}$ . Samples were embedded in paraffin, and serial  $5 \mu\text{m}$  cross-sections in a plane parallel to the surface of the tissue were obtained at intervals of  $50 \mu\text{m}$ . Three sections were counterstained with hematoxylin and  
25 eosin, and 3 sections were counterstained with Masson's trichrome. Random fields were generated by computer, and sections were examined at a magnification of x400 in a blinded fashion, by a pathologist not associated with the study. Five fields were counted per slide, with a minimum of  
30 4 vessels  $< 20 \mu\text{m}$  counted per field; 6 slides were evaluated per animal. The counts were averaged, and reported as vessel number per  $\text{mm}^2$ . Results were reported as mean  $\pm$  standard error of the mean. Statistical analysis was performed by the unpaired two-tailed Student's t-test.

35 Enhanced vascularity was observed (100x and 600x magnification) following delivery of  $10^{11}$  pfu of AdCMV.VEGF to rat retroperitoneal adipose tissue, but not following

41

delivery of  $10^{11}$  pfu of Ad.RSV $\beta$ gal. Similarly, photomicrographs taken *in vivo* of retroperitoneal adipose tissue demonstrated a marked increase in vascularity at longer times following administration of AdCMV.VEGF. In particular, evaluation 30 days after AdCMV.VEGF administration showed several-fold more vessels in adipose tissue as compared to adipose tissue of naive animals, animals receiving the control AdCMV.Null vector, and the contralateral (untreated) adipose tissue of animals receiving the AdCMV.VEGF vector to the opposite side. Quantitative assessment of the vessel number showed an increase in the number of blood vessels in the adipose tissue 10 days after the administration of AdCMV.VEGF which was 667% that of the uninjected contralateral control adipose tissue in the same animals, and 310% and 256% that of the sham and AdCMV.Null control adipose tissue, respectively ( $p < 0.01$ , all comparisons, Figure 4). Importantly, the increase in the quantitative *in vivo* blood vessel counts were maintained in the adipose tissue 20 and 30 days following vector administration ( $p < 0.004$ , all comparisons), despite the fact that VEGF could not be detected in the adipose tissue at day 10 following administration of the AdCMV.VEGF.

Histologic evaluation of capillary number was consistent with the observations made of *in vivo* blood vessel quantification. For these experiments, all samples were examined at a magnification of 400x, and were counterstained with  $\alpha$ -actin. In the AdCMV.VEGF-injected tissue, histologic evaluation showed more capillaries 30 days after vector administration compared to the naive and AdCMV.Null-injected controls, as well as the contralateral (untreated) adipose tissue of an animal injected with the AdCMV.VEGF vector. Quantitative assessment of the histologic samples (Figure 5) showed a 21 to 39% increase in capillary number in the AdCMV.VEGF-injected adipose tissue compared to the AdCMV.Null controls at days 5, 10, 20, and 30 ( $p < 0.0002$ , all comparisons), i.e., as with the *in vivo* blood vessel quantification of vessels observed at 30x magnification, there was persistence in the increased capillary number

42

despite the fact that VEGF could not be detected at day 10 and thereafter.

These results confirm that adenoviral-mediated gene transfer to adipocytes *in vivo* can be employed to attain a therapeutic effect. In particular, the results validate that an adenoviral vector carrying the VEGF cDNA is capable of inducing the growth of new blood vessels in a regional fashion in relatively avascular, normal tissue. This indicates that *in vivo* adenoviral-mediated gene transfer can be used, *inter alia*, for therapeutic angiogenesis with respect to adipocytes.

All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference. The section headings or captions preceding various portions of the text are used to index or divide the text but should not be construed to denote or imply any limitations on the scope of the invention.

While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations in the preferred embodiments can be used, including variations due to improvements in the art, and that the invention can be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.

WHAT IS CLAIMED IS:

1. A method of modifying an adipocyte *in vivo* which comprises contacting said adipocyte with an adenoviral vector comprising a promoter and, operably linked thereto, a nucleic acid sequence encoding a therapeutic protein or a therapeutic mRNA so as to effect entry of said adenoviral vector into said adipocyte, expression of said nucleic acid sequence, and production of said protein or mRNA.

2. The method of claim 1, wherein said adenoviral vector is replication-deficient.

3. The method of claim 1 or 2, wherein said protein is selected from the group consisting of a secreted protein which acts systemically and a protein which acts upon or in the vicinity of said adipocyte.

4. The method of claim 1 or 2, wherein said protein is selected from the group consisting of a toxin, an angiogenic growth factor, an adipsin, and an Ob protein.

5. The method of any of claims 1-4, wherein said promoter is an adipocyte-specific promoter.

6. The method of claim 5, wherein said promoter is selected from the group consisting of the aP2 gene regulatory region and the p154 polypeptide gene regulatory region.

7. The method of any of claims 1-5, wherein said promoter is a constitutive promoter.

8. The method of any of claims 1-7, wherein said method further comprises transferring said adipocyte to another site within a host.

9. The method of any of claims 1-8, wherein said method is employed in the treatment of an energy storage

*44*

disorder selected from the group consisting of obesity, diabetes, increased body fat deposition, hyperglycemia, hyperinsulinemia, hypothermia, hypertension, hypercholesterolemia, and hyperlipidemia.

10. The method of any of claims 1-8, wherein said method is employed to stimulate angiogenesis.

11. An adenoviral vector comprising an adipocyte specific promoter and, operably linked thereto, a nucleic acid sequence encoding a therapeutic protein or therapeutic mRNA.

12. The vector of claim 11, wherein said vector is replication-deficient.

13. The vector of claim 11 or 12, wherein said promoter is selected from the group consisting of the aP2 gene regulatory region and the p154 polypeptide gene regulatory region.

14. The vector of any of claims 11-13, wherein said protein is selected from the group consisting of a secreted protein which acts systemically and a protein which acts upon or in the vicinity of said adipocyte.

15. The vector of any of claims 11-14, wherein said protein is selected from the group consisting of a toxin, an angiogenic growth factor, an adipsin, and an Ob protein.

16. A host cell comprising the vector of any of claims 11-15.

17. An adipocyte comprising an adenoviral vector comprising a constitutive promoter and, operably linked thereto, a nucleic acid sequence encoding a protein selected from the group consisting of a secreted protein which acts systemically and a protein which acts upon or in the vicinity of an adipocyte.

45

18. The vector of claim 17, wherein said vector is replication-deficient.

19. An adipocyte comprising an adenoviral vector comprising a promoter and, operably linked thereto, a nucleic acid sequence encoding a protein selected from the group consisting of a toxin, an angiogenic growth factor, an adipsin, and an Ob protein.

20. The vector of claim 19, wherein said vector is replication-deficient.

21. An adipose tissue implant comprising (a) adipose tissue isolated from a donor for implantation into a host and (b) an angiogenic substance in context with said adipose tissue.

22. The adipose tissue implant of claim 21, wherein said angiogenic substance is an isolated angiogenic protein or an angiogenic composition comprising an angiogenic protein and a pharmaceutically acceptable carrier.

23. The adipose tissue implant of claim 21, wherein said angiogenic substance is a gene transfer vector comprising an angiogenic gene.

24. The adipose tissue implant of claim 21, wherein said adipose tissue is contacted with both of a gene transfer vector comprising an angiogenic gene and an angiogenic protein.

25. The adipose tissue implant of any of claims 21-24, wherein said adipose tissue implant further comprises a lymphogenic protein or a gene transfer vector comprising a lymphogenic gene in context with said adipose tissue.

26. The adipose tissue implant of any of claims 21-25, wherein said donor and said host are the same.


46



27. The adipose tissue implant of any of claims 21-26, wherein said angiogenic substance is a VEGF protein.


28. The adipose tissue implant of any of claims 21-26, wherein said angiogenic substance is a gene transfer vector comprising a gene encoding a VEGF protein.

1 / 5


**FIG. 1**

SUBSTITUTE SHEET (RULE 26)


2 / 5

**FIG. 2**


3 / 5

**FIG. 3**

4 / 5

**FIG. 4**

5 / 5

**FIG. 5**

SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  
C12N 15/86, A61K 48/00, C12N 5/10,  
5/06, A61F 2/02, C07K 14/52, A61K 35/12

A3

(11) International Publication Number: WO 97/4982

(43) International Publication Date: 31 December 1997 (31.12.97)

(21) International Application Number: PCT/US97/11229

(22) International Filing Date: 26 June 1997 (26.06.97)

(30) Priority Data:  
08/672,461 26 June 1996 (26.06.96) US

(60) Parent Application or Grant  
(63) Related by Continuation  
US  
Filed on 08/672,461 (CIP)  
26 June 1996 (26.06.96)

(71) Applicant (for all designated States except US): CORNELL  
RESEARCH FOUNDATION, INC. [US/US]; Cornell Busi-  
ness and Technology Park, Suite 105, 20 Thornwood Drive,  
Ithaca, NY 14850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CRYSTAL, Ronald, G.  
[US/US]; 13712 Canal Vista Court, Potomac, MD 20852  
(US). MAGOVERN, Christopher, J. [US/US]; Apartment  
33F, 435 E. 70th Street, New York, NY 10021 (US).  
ROSENGART, Todd [US/US]; 2 Dogwood Lane, Tenafly,  
NJ 07670 (US). HOFFMAN, Lloyd [US/US]; 11 Lin-  
coln Road, Great Neck, NY 11021 (US). TALMOR, Mia

[US/US]; Apartment 29A, 1320 York Avenue, New York  
NY 10021 (US).

(74) Agents: KILYK, John, Jr. et al.; Leydig, V it & Mayer, Ltd  
Suite 4900, Two Prudential Plaza, Chicago, IL 60601-678  
(US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR  
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE  
HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT  
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT  
RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG  
US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ  
UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD,  
RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,  
TG).


Published

With international search report.

Before the expiration of the time limit for amending the claims  
and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:  
12 March 1998 (12.03.98)

(54) Title: ADENOVIRAL MEDIATED GENE TRANSFER IN ADIPOCYTES AND RELATED IMPLANTS



## (57) Abstract

The present invention provides gene transfer to adipocytes mediated by adenovirus and, in particular, transfer of toxic genes as a means of reducing adiposity and transfer of genes encoding angiogenic substances to induce new blood vessel growth, as well as adipose tissue implants.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PL | Poland                                       |    |                          |
| CN | China                    | KZ | Kazakhstan                               | PT | Portugal                                     |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SD | Sudan  |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SE | Sweden                                       |    |                          |
| EE | Estonia                  |    |  | SG | Singapore                                    |    |                          |



# INTERNATIONAL SEARCH REPORT

Intern. Application No  
PCT/US 97/11229

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 A61K48/00 C12N5/10 C12N5/06 A61F2/02  
C07K14/52 A61K35/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K A61F C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.  |
|------------|---|------------------------|
| X          | SETOGUCHI, Y. ET AL.: "Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors"<br>JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 102, no. 4, April 1994, pages 415-421, XP002044071<br>cited in the application | 1-3,7,<br>16-18        |
| Y          | see the whole document<br>---   | 1-21,<br>23-28<br>-/-- |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

16 January 1998

Date of mailing of the international search report

03.02.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

## INTERNATIONAL SEARCH REPORT

Internat! Application No  
PCT/US 97/11229

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.   |
|------------|---|-------------------------|
| X          | CLAYMAN, G.L. ET AL.: "Transduction of normal and malignant oral epithelium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration"<br>CANCER GENE THERAPY,<br>vol. 2, no. 2, June 1995,<br>pages 105-111, XP002044072<br>cited in the application        | 1-3,7,<br>16-18         |
| Y          | see page 107, column 2, paragraph 1;<br>figure 1C   | 1-21,<br>23-28          |
| X          | ---<br>EPPLEY, B.L. ET AL.: "bioACTIVATION OF FREE-FAT TRANSFERS: A POTENTIAL NEW APPROACH TO IMPROVING GRAFT SURVIVAL".<br>PLASTIC AND RECONSTRUCTIVE SURGERY,<br>vol. 90, no. 6, December 1992,<br>pages 1022-1030, XP002052281<br>see page 1027, paragraph 2   | 21,22                   |
| Y          | ---<br>ROSS, S.R. ET AL.: "Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity"<br>GENES & DEVELOPMENT,<br>vol. 7, no. 7b, July 1993,<br>pages 1318-1324, XP002044074<br>cited in the application<br>see the whole document   | 23-26                   |
| Y          | ---<br>WO 95 19434 A (CALYDON INC) 20 July 1995<br>see page Y; claims 5,6,9,10,14-16  | 1-6,9,<br>11-20         |
| Y          | ---<br>MÜHLHAUSER, J. ET AL.: "VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo"<br>CIRCULATION RESEARCH,<br>vol. 77, no. 6, December 1995,<br>pages 1077-1086, XP002044444<br>see the whole document  | 1-7,<br>10-21,<br>23-28 |
| Y          | ---<br>SETOGUCHI Y ET AL: "STIMULATION OF ERYTHROPOIESIS BY IN VIVO GENE THERAPY: PHYSIOLOGIC CONSEQUENCES OF TRANSFER OF THE HUMAN ERYTHROPOIETIN GENE TO EXPERIMENTAL ANIMALS USING AN ADENOVIRUS VECTOR"<br>BLOOD,<br>vol. 84, no. 9, 1 November 1994,<br>pages 2946-2953, XP000562146<br>see the whole document | 1-9,<br>11-20           |
|            | ---<br>-/-  |                         |

# INTERNATIONAL SEARCH REPORT

Internā Application No  
PCT/US 97/11229

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |   |                       |
|--|---|-----------------------|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
| A  | EP 0 518 389 A (UNIV JEFFERSON) 16<br>December 1992<br>see the whole document   | 21                    |
| X,P  | ---<br>KATAGIRI, H. ET AL.: "Overexpression of<br>catalytic subunit p110alpha of<br>phosphatidylinositol 3-kinase increases<br>glucose transport activity with<br>translocation of glucose transporters in<br>3T3-L1 adipocytes"<br>JOURNAL OF BIOLOGICAL CHEMISTRY.<br>(MICROFILMS),<br>vol. 271, no. 29, 19 July 1996, MD US,<br>pages 16987-16990, XP002044073<br>see the whole document | 17,18                 |
| Y,P  | ---<br>see the whole document   | 1-21,<br>23-28        |
| P,X  | WO 96 40172 A (LIFE MEDICAL SCIENCES INC)<br>19 December 1996<br>see page 1, line 1 - page 3, paragraph 3   | 21,22,26              |
| P,Y  | see page 17, line 5 - line 17; claims<br>18,32-41   | 21,23-28              |
| P,Y  | ---<br>YAMAMOTO, K. ET AL.: "Human VEGF gene<br>transfer into vascular prosthesis"<br>CIRCULATION,<br>vol. 94, no. 8, 15 October 1996,<br>page I-637 XP002044445<br>see abstract 3721<br>-----  | 21,23-28              |

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 11229

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: As far as claims 1-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see continuation-sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 1. Claims: 1-20 and partially 21, 23-28

An adenoviral vector for modifying an adipocyte in vivo, comprising a promoter and, operably linked thereto, a nucleic acid sequence encoding a therapeutic protein or a therapeutic mRNA so as to effect entry of said adenoviral vector into said adipocyte, expression of said nucleic acid sequence and production of said protein or mRNA; a host cell comprising said vector; an adipose tissue implant comprising a) adipose tissue isolated from a donor for implantation into a host and b) said vector encoding an angiogenic growth factor.

## 2. Claims: 22 and partially 21, 23-28

An adipose tissue implant comprising a) adipose tissue isolated from a donor for implantation into a host and b) an angiogenic substance in context with said adipose tissue in the case said angiogenic substance is not a vector described in the first subject, that means an adenoviral vector encoding an angiogenic growth factor.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/11229

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO 9519434 A                              | 20-07-95            | AU 1686995 A               | 01-08-95            |
|   |                     | CA 2181073 A               | 20-07-95            |
|   |                     | EP 0755443 A               | 29-01-97            |
|   |                     | JP 9509049 T               | 16-09-97            |
|   |                     | US 5648478 A               | 15-07-97            |
|   |                     |                            |                     |
| • EP 0518389 A                            | 16-12-92            | US 4820626 A               | 11-04-89            |
|   |                     | AT 113850 T                | 15-11-94            |
|   |                     | AU 590573 B                | 09-11-89            |
|   |                     | AU 5830586 A               | 11-12-86            |
|   |                     | BR 8602659 A               | 03-02-87            |
|   |                     | CA 1293700 A               | 31-12-91            |
|   |                     | DE 3650134 D               | 15-12-94            |
|   |                     | DE 3650134 T               | 22-06-95            |
|   |                     | EP 0206025 A               | 30-12-86            |
|   |                     | JP 62049857 A              | 04-03-87            |
|   |                     | MX 165125 B                | 28-10-92            |
|   |                     | US 5441539 A               | 15-08-95            |
|   |                     | US 5035708 A               | 30-07-91            |
|   |                     | US 5194373 A               | 16-03-93            |
|   |                     | US 5230693 A               | 27-07-93            |
|   |                     | US 5372945 A               | 13-12-94            |
|   |                     | US 5312380 A               | 17-05-94            |
|   |                     | US 5628781 A               | 13-05-97            |
|   |                     | US 5131907 A               | 21-07-92            |
|   |                     |                            |                     |
| WO 9640172 A                              | 19-12-96            | US 5681561 A               | 28-10-97            |
|   |                     | AU 6095596 A               | 30-12-96            |